299 related articles for article (PubMed ID: 7344017)
1. [Clinically apparent liver damage during brief tuberculosis therapy].
Estay S; Armas Merino R; Vega C; Soto JR
Rev Med Chil; 1981 Oct; 109(10):941-4. PubMed ID: 7344017
[No Abstract] [Full Text] [Related]
2. Summaries for patients. Short-course treatment for latent tuberculosis is associated with more frequent liver injury than long-course treatment is.
Ann Intern Med; 2002 Oct; 137(8):I32. PubMed ID: 12379094
[No Abstract] [Full Text] [Related]
3. [Fulminant hepatitis in the course of antitubercular treatment (apropos of 2 cases)].
Mbaye PS; Talarmin F; Sane M; Eladari D; Klotz F
Dakar Med; 1995; 40(2):129-31. PubMed ID: 9827070
[TBL] [Abstract][Full Text] [Related]
4. Hepatotoxicity of rifampin-pyrazinamide and isoniazid preventive therapy and tuberculosis treatment.
van Hest R; Baars H; Kik S; van Gerven P; Trompenaars MC; Kalisvaart N; Keizer S; Borgdorff M; Mensen M; Cobelens F
Clin Infect Dis; 2004 Aug; 39(4):488-96. PubMed ID: 15356811
[TBL] [Abstract][Full Text] [Related]
5. [Toxicity of antitubercular agents for the liver].
Dölle W
Dtsch Med Wochenschr; 1973 Jan; 98(2):74. PubMed ID: 4683834
[No Abstract] [Full Text] [Related]
6. From the Centers for Disease Control and Prevention. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
JAMA; 2001 May 23-30; 285(20):2572-3. PubMed ID: 11396466
[No Abstract] [Full Text] [Related]
7. From the Centers for Disease Control and Prevention. Update: Fatal and severe liver injuries associated with Rifampin and Pyrazinamide for latent tuberculosis infection, and revisions in American Thoracic Society/CDC recommendations--United States, 2001.
JAMA; 2001 Sep; 286(12):1445-6. PubMed ID: 11596606
[No Abstract] [Full Text] [Related]
8. Antitubercular drugs (isoniazid, rifampin and pyrazinamide): hepatobiliary reactions.
Vu D; Macdonald L
CMAJ; 2001 Oct; 165(7):942-3, 946-7. PubMed ID: 11599338
[No Abstract] [Full Text] [Related]
9. Hepatotoxicity of pyrazinamide: cohort and case-control analyses.
Chang KC; Leung CC; Yew WW; Lau TY; Tam CM
Am J Respir Crit Care Med; 2008 Jun; 177(12):1391-6. PubMed ID: 18388355
[TBL] [Abstract][Full Text] [Related]
10. [Side effects of various combinations of rifampin and isoniazid with ethambutol or streptomycin and pyrazinamide in short-term chemotherapy of newly-detected pulmonary tuberculosis].
Zierski M; Bek E
Pneumonol Pol; 1980 Jul; 48(7):469-79. PubMed ID: 7433146
[No Abstract] [Full Text] [Related]
11. Fatal and severe hepatitis associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection--New York and Georgia, 2000.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2001 Apr; 50(15):289-91. PubMed ID: 11330495
[TBL] [Abstract][Full Text] [Related]
12. Adverse effects of antituberculosis drugs.
Girling DJ
Drugs; 1982; 23(1-2):56-74. PubMed ID: 6459920
[No Abstract] [Full Text] [Related]
13. Antituberculosis drugs and hepatotoxicity.
Sharma SK
Infect Genet Evol; 2004 Jun; 4(2):167-70. PubMed ID: 15157635
[No Abstract] [Full Text] [Related]
14. [Hepatic functional changes induced by the combined use of isoniazid, pyrazinamide and rifampicin in the treatment of pulmonary tuberculosis].
de Souza AF; de Oliveira e Silva A; Baldi J; de Souza TN; Rizzo PM
Arq Gastroenterol; 1996; 33(4):194-200. PubMed ID: 9302332
[TBL] [Abstract][Full Text] [Related]
15. [Liver damage from tuberculosis treatment].
Keiner F
Med Klin; 1981 Jun; 76(13):376-7. PubMed ID: 7254121
[No Abstract] [Full Text] [Related]
16. [Characteristics of drug-induced hepatitis in patients with tuberculosis].
Vil'derman AM
Probl Tuberk; 1972; 50(5):59-63. PubMed ID: 4112966
[No Abstract] [Full Text] [Related]
17. The best approach to reintroducing tuberculosis treatment after hepatotoxicity is still open to debate.
Chang KC; Leung CC
Clin Infect Dis; 2010 Aug; 51(3):366-7; author reply 367-8. PubMed ID: 20597681
[No Abstract] [Full Text] [Related]
18. Side effects of drugs used to treat tuberculosis.
Newton RW
Scott Med J; 1975 Mar; 20(2):47-9. PubMed ID: 47648
[No Abstract] [Full Text] [Related]
19. Adverse drug reactions in TB therapy: risks and recommendations.
Yoshikawa TT; Nagami PH
Geriatrics; 1982 Jul; 37(7):61-8. PubMed ID: 7084671
[No Abstract] [Full Text] [Related]
20. [Liver injury under tuberculostatic treatment].
Fattinger K; Braunschweig S; Reichen J; Meier-Abt PJ; Krähenbühl S
Praxis (Bern 1994); 1997 Apr; 86(15):626-9. PubMed ID: 9213916
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
